SillaJen, Inc. (215600.KQ)
KRW 2565.0
(0.79%)
KRW 2565.0
(0.79%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -17.35 Billion KRW | 12.57% |
| 2022 | -20.62 Billion KRW | -20.84% |
| 2021 | -18.17 Billion KRW | 41.58% |
| 2020 | -44.42 Billion KRW | 40.28% |
| 2019 | -104.4 Billion KRW | 1.06% |
| 2018 | -51.38 Billion KRW | -18.87% |
| 2017 | -48.84 Billion KRW | -8.69% |
| 2016 | -62.44 Billion KRW | -111.44% |
| 2015 | -42.81 Billion KRW | -58.62% |
| 2014 | -12.86 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.75 Billion KRW | 17.96% |
| 2024 Q2 | -6.39 Billion KRW | -38.04% |
| 2023 Q3 | -5.37 Billion KRW | -1.78% |
| 2023 FY | - KRW | 12.57% |
| 2023 Q4 | -5.84 Billion KRW | -8.74% |
| 2023 Q1 | -3.62 Billion KRW | 55.37% |
| 2023 Q2 | -5.28 Billion KRW | -45.55% |
| 2022 Q2 | -4.4 Billion KRW | 14.23% |
| 2022 FY | - KRW | -20.84% |
| 2022 Q1 | -5.14 Billion KRW | 25.85% |
| 2022 Q4 | -8.12 Billion KRW | -45.93% |
| 2022 Q3 | -5.57 Billion KRW | -26.32% |
| 2021 Q2 | -4.09 Billion KRW | -5.32% |
| 2021 Q4 | -6.93 Billion KRW | -60.6% |
| 2021 FY | - KRW | 41.58% |
| 2021 Q1 | -3.89 Billion KRW | -11.6% |
| 2021 Q3 | -4.31 Billion KRW | -5.34% |
| 2020 FY | - KRW | 40.28% |
| 2020 Q4 | -3.48 Billion KRW | 54.87% |
| 2020 Q3 | -7.72 Billion KRW | 33.87% |
| 2020 Q2 | -11.68 Billion KRW | -16.38% |
| 2020 Q1 | -10.03 Billion KRW | 31.25% |
| 2019 Q3 | -16.35 Billion KRW | -72.29% |
| 2019 Q1 | -14.7 Billion KRW | -29.48% |
| 2019 FY | - KRW | 1.06% |
| 2019 Q4 | -14.6 Billion KRW | 10.72% |
| 2019 Q2 | -9.49 Billion KRW | 35.45% |
| 2018 Q2 | -14.54 Billion KRW | -5.12% |
| 2018 Q4 | -11.35 Billion KRW | 29.03% |
| 2018 Q3 | -16 Billion KRW | -10.01% |
| 2018 FY | - KRW | -18.87% |
| 2018 Q1 | -13.83 Billion KRW | -10.98% |
| 2017 Q2 | -16.08 Billion KRW | -72.97% |
| 2017 FY | - KRW | -8.69% |
| 2017 Q1 | -9.3 Billion KRW | 40.39% |
| 2017 Q4 | -12.46 Billion KRW | -37.98% |
| 2017 Q3 | -9.03 Billion KRW | 43.83% |
| 2016 Q4 | -15.6 Billion KRW | -47.11% |
| 2016 Q2 | -9.93 Billion KRW | -41.81% |
| 2016 Q1 | -7 Billion KRW | -22.07% |
| 2016 FY | - KRW | -111.44% |
| 2016 Q3 | -10.6 Billion KRW | -6.81% |
| 2015 Q3 | -6.2 Billion KRW | -42.69% |
| 2015 Q4 | -5.73 Billion KRW | 7.61% |
| 2015 Q2 | -4.35 Billion KRW | -5.99% |
| 2015 Q1 | -4.1 Billion KRW | 3.17% |
| 2015 FY | - KRW | -58.62% |
| 2014 FY | - KRW | 0.0% |
| 2014 Q2 | -3.41 Billion KRW | -92.35% |
| 2014 Q3 | -3.43 Billion KRW | -0.47% |
| 2014 Q4 | -4.24 Billion KRW | -23.55% |
| 2014 Q1 | -1.77 Billion KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 89.928% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | -178.323% |
| BINEX Co., Ltd. | 10.87 Billion KRW | 259.606% |
| Bioneer Corporation | 10.04 Billion KRW | 272.778% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | -3863.339% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | 10.516% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 59.454% |
| Helixmith Co., Ltd | -53 Billion KRW | 67.262% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 124.758% |
| Medy-Tox Inc. | 32.69 Billion KRW | 153.069% |
| Peptron, Inc. | -12.65 Billion KRW | -37.168% |
| Amicogen, Inc. | 13.95 Billion KRW | 224.362% |
| Genexine, Inc. | -40.87 Billion KRW | 57.551% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | 310.855% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 75.692% |
| ALTEOGEN Inc. | 440.04 Million KRW | 4043.369% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 116.644% |
| JETEMA, Co., Ltd. | 11 Billion KRW | 257.639% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | -55.836% |
| Genomictree Inc. | -6.33 Billion KRW | -174.051% |
| MedPacto, Inc. | -32.6 Billion KRW | 46.786% |
| D&D Pharmatech | -9.05 Billion KRW | -91.573% |
| EASY BIO,Inc. | 24.32 Billion KRW | 171.341% |
| GI Innovation, Inc. | -51.33 Billion KRW | 66.195% |